Body Fat Reduction Effect of Bifidobacterium breve B-3: A Randomized, Double-Blind, Placebo Comparative Clinical Trial

This double-blind, randomized clinical trial aimed to evaluate the efficacy and safety of Bifidobacterium breve B-3 (BB-3) for reducing body fat. Healthy individuals were randomized into the BB-3 or placebo group (1:1). Dual-energy X-ray absorptiometry was used to evaluate body fat reduction objectively. In the BB-3 group, body weight was lower than before BB-3 ingestion. Regarding waist circumference, hip circumference, and waist/hip circumference ratio, waist circumference and hip circumference were lower in the BB-3 group than in the placebo group at 12 weeks; the waist/hip circumference ratio was found to decrease at each visit in the BB-3 group, although there was no significant difference in the amount of change after 12 weeks. BB-3 did not cause any severe adverse reactions. Body fat was significantly lower in the BB-3 group than in the placebo group. In conclusion, ingesting BB-3 significantly reduces body weight, waist circumference, and hip circumference. Thus, BB-3 is safe and effective for reducing body fat.

[1]  James D. Johnson,et al.  Competing paradigms of obesity pathogenesis: energy balance versus carbohydrate-insulin models , 2022, European Journal of Clinical Nutrition.

[2]  E. Ravussin,et al.  The energy balance model of obesity: beyond calories in, calories out. , 2022, The American journal of clinical nutrition.

[3]  Jianhong Wu,et al.  The global burden of disease attributable to high body mass index in 195 countries and territories, 1990–2017: An analysis of the Global Burden of Disease Study , 2020, PLoS medicine.

[4]  Xiaoxia Song,et al.  Global burden of noncommunicable disease attributable to high body mass index in 195 countries and territories, 1990–2017 , 2020, Endocrine.

[5]  D. Kalman,et al.  Body Composition Changes in Weight Loss: Strategies and Supplementation for Maintaining Lean Body Mass, a Brief Review , 2018, Nutrients.

[6]  B. Rinaldi,et al.  AT1-receptor blockade: Protective effects of irbesartan in cardiomyocytes under hypoxic stress , 2018, PloS one.

[7]  R. Kelishadi,et al.  Association of exposure to Bisphenol A with obesity and cardiometabolic risk factors in children and adolescents , 2018, International journal of environmental health research.

[8]  K. Yamauchi,et al.  Effects of Bifidobacterium breve B-3 on body fat reductions in pre-obese adults: a randomized, double-blind, placebo-controlled trial , 2018, Bioscience of microbiota, food and health.

[9]  Magnus Borga,et al.  Advanced body composition assessment: from body mass index to body composition profiling , 2018, Journal of Investigative Medicine.

[10]  J. Hjelmesæth,et al.  Effects of probiotics on body weight, body mass index, fat mass and fat percentage in subjects with overweight or obesity: a systematic review and meta‐analysis of randomized controlled trials , 2018, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[11]  J. Kang,et al.  Effect of a herbal extract powder (YY-312) from Imperata cylindrica Beauvois, Citrus unshiu Markovich, and Evodia officinalis Dode on body fat mass in overweight adults: a 12-week, randomized, double-blind, placebo-controlled, parallel-group clinical trial , 2017, BMC Complementary and Alternative Medicine.

[12]  Joshua A. Salomon,et al.  Health Effects of Overweight and Obesity in 195 Countries over 25 Years. , 2017, The New England journal of medicine.

[13]  Philipp E. Scherer,et al.  Obesity, Diabetes, and Cardiovascular Diseases: A Compendium. , 2016, Circulation research.

[14]  Shota Takahashi,et al.  Effect of Bifidobacterium animalis ssp. lactis GCL2505 on visceral fat accumulation in healthy Japanese adults: a randomized controlled trial , 2016, Bioscience of microbiota, food and health.

[15]  Kayoung Lee.  Long-term Weight Loss Maintenance , 2015 .

[16]  T. Odamaki,et al.  Oral administration of Bifidobacterium breve B-3 modifies metabolic functions in adults with obese tendencies in a randomised controlled trial , 2015, Journal of Nutritional Science.

[17]  R. Brummer,et al.  The development of probiotic treatment in obesity: a review. , 2014, Beneficial microbes.

[18]  K. Abe,et al.  Bifidobacterium breve B-3 exerts metabolic syndrome-suppressing effects in the liver of diet-induced obese mice: a DNA microarray analysis. , 2013, Beneficial microbes.

[19]  J. Fernández-Real,et al.  Gut microbiota interactions with obesity, insulin resistance and type 2 diabetes: did gut microbiote co-evolve with insulin resistance? , 2011, Current opinion in clinical nutrition and metabolic care.

[20]  G. Musso,et al.  Obesity, Diabetes, and Gut Microbiota , 2010, Diabetes Care.

[21]  K. Abe,et al.  Antiobesity Effects of Bifidobacterium breve Strain B-3 Supplementation in a Mouse Model with High-Fat Diet-Induced Obesity , 2010, Bioscience, biotechnology, and biochemistry.

[22]  K. Imaizumi,et al.  Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial , 2010, European Journal of Clinical Nutrition.

[23]  T. van de Wiele,et al.  Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability , 2009, Gut.

[24]  M. Crowell,et al.  Human gut microbiota in obesity and after gastric bypass , 2009, Proceedings of the National Academy of Sciences.

[25]  Y. Yang,et al.  Validity and Reliability of Korean Version of International Physical Activity Questionnaire (IPAQ) Short Form. , 2007 .

[26]  P. Turnbaugh,et al.  Microbial ecology: Human gut microbes associated with obesity , 2006, Nature.

[27]  F. Bäckhed,et al.  Obesity alters gut microbial ecology. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[28]  D. Drucker,et al.  Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. , 2004, Endocrinology.

[29]  T. Sane,et al.  Health-related quality of life in obese outpatients losing weight with very-low-energy diet and behaviour modification—a 2-y follow-up study , 2003, International Journal of Obesity.

[30]  P. Froguel,et al.  Globular Adiponectin Protected ob/ob Mice from Diabetes and ApoE-deficient Mice from Atherosclerosis* , 2003, The Journal of Biological Chemistry.

[31]  Kenichi Yoshida,et al.  Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase Published, JLR Papers in Press, September 16, 2002. DOI 10.1194/jlr.C200010-JLR200 , 2002, Journal of Lipid Research.

[32]  OUP accepted manuscript , 2022, The American Journal of Clinical Nutrition.

[33]  J. Kaprio,et al.  The genetic and environmental influences on childhood obesity: a systematic review of twin and adoption studies , 2010, International Journal of Obesity.